LSX World Congress Europe

Next week, our CEO Jan Thirkettle will be attending the LSX World Congress Europe in London (April 28-30, 2025) to meet decision makers, investors, business development teams, R&D leaders and industry KOLs, to advance healthcare innovation.

We're excited to be sharing our progress on our antisense oligonucleotide (ASO) approach targeting FAN1 for Huntington's Disease treatment and exploring potential collaboration opportunities with partners who share our commitment to addressing neurodegenerative diseases through novel therapeutic approaches.

If you're attending #LSXWorldCongress, reach out and connect with Jan.

More information about the congress is available here.

#LSXWorldCongress #HarnessTherapeutics #Biotech #HuntingtonsDisease #NeurodegenerativeDiseases #Partnering #LifeSciences

Our programmes

Huntington's Disease

Discover more

ALS and Alzheimer's

Discover more

Our news

June 2025

Harness Therapeutics Publishes HTT CAG Repeat Sizing Methodology Code on GitHub

February 2025

Harness Therapeutics to Present Nanopore Sequencing Data for Detecting CAG Expansion in the Huntingtin Gene at CHDI Huntington’s Disease Therapeutics Conference

January 2025

Harness Therapeutics appoints Dr Heather Preston as Chair and secures new funding from Ono Venture Investment to accelerate delivery of transformational neurodegeneration pipeline

September 2024

Harness Therapeutics Appoints Experienced R&D Executive and Physician-Scientist, Dr Paulo Fontoura, as Non-Executive Director

View all